In fact, first-dose bradycardia is a recognized pharmacodynamic effect of S1P modulators, and cases of transient sinus bradycardia or atrioventricular block have been documented with Etrasimod (Vermeire et al., 2025). Here, MBTPS1 is linked to Sinus bradycardia.